<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01566591</url>
  </required_header>
  <id_info>
    <org_study_id>BR-BIP-03</org_study_id>
    <nct_id>NCT01566591</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Deep Transcranial Magnetic Stimulation in Bipolar Depression</brief_title>
  <official_title>A Prospective, Double Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the H1-Coil Deep Transcranial Magnetic Stimulation (TMS) in Conjunction With Mood Stabilizers in Subjects With Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brainsway</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brainsway</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of H1-Coil deep brain rTMS in
      subjects with bipolar depression, taking mood stabilizers and previously unsuccessfully
      treated with antidepressant medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi center, randomized, double blind study to evaluate the efficacy and safety of
      H1-Coil deep brain rTMS in subjects with bipolar depression, taking mood stabilizers and
      previously unsuccessfully treated with antidepressant medications. The study is designed for
      a period of 8 weeks of which up to 3 weeks subjects will be tapered down from their
      medications and treated for 5 weeks. Two follow up visits will be performed at week 6 and 8
      after the last TMS treatment. Mood and mental status will be closely monitored with standard
      psychological scales and assessments
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HDRS-21 Score measured by change from baseline.</measure>
    <time_frame>6 weeks from baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical antidepressant remission rate at the 6-week visit</measure>
    <time_frame>6 weeks from baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>Sham Treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deep TMS Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deep TMS treatment is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Deep TMS Treatment</intervention_name>
    <description>24 TMS treatments over 6 weeks .</description>
    <arm_group_label>Deep TMS Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Treatment</intervention_name>
    <description>24 TMS treatments over 6 weeks</description>
    <arm_group_label>Sham Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients

          -  patients suffering from an episode of bipolar depression (BP1 or BP2) according to DSM
             IV, with the additional requirement of duration for the current episode ≥ 4 weeks and
             CGI ≥ 4.

          -  Men and Women Ages 22-68 years.

          -  Negative answers on safety screening questionnaire for transcranial magnetic
             stimulation.

          -  Taking mood stabilizing medication (e.g., Lithium, Lamictal, Tegretol, Topamax, etc.)
             at a therapeutic dose or atypical antipsychotic medication which was prescribed as
             mood stabilizers by their treating physician, except for Leponex (Clozapine).
             According to the treating physician the patient is compliant with taking the
             mood-stabilizing medication.

        Exclusion Criteria:

          -  patients suffering from other diagnoses on axis 1 such as schizophrenia , or suffering
             from psychotic depression in current episode.

          -  Diagnosed as suffering from Severe Borderline Personality Disorder or hospitalized due
             to exacerbation related to of borderline personality disorder. Subjects suffering from
             any other Severe Personality Disorder will also be excluded.

          -  Present suicidal risk as assessed by the investigator

          -  Patients with a bipolar cycle of less than 30 days.

          -  History of epilepsy or seizure (EXCEPT those therapeutically induced by ECT ) or
             history of such in first degree relatives.

          -  Increased risk of seizure for any reason, including prior diagnosis of increased
             intracranial pressure (such as after large infarctions or trauma), or history of
             significant head trauma with loss of consciousness for greater than or equal to 5
             minutes.

          -  History of head injury.

          -  History of any metal in the head (outside the mouth).

          -  Metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines,
             implanted neurostimulators, intracranial implant (e.g., aneurysm clips, shunts,
             stimulators, cochlear implants, or electrodes) or implanted medical pumps.

          -  Hearing loss.

          -  Individuals with a significant neurological disorder or insult including, but not
             limited to:

               -  Any condition likely to be associated with increased intracranial pressure

               -  Space occupying brain lesion

               -  History of cerebrovascular accident

               -  Transient ischemic attack within two years

               -  Cerebral aneurysm

               -  Dementia

               -  Parkinson's disease

               -  Huntington's chorea

               -  Multiple sclerosis

          -  Current History of substance abuse including alcoholism or history of substance abuse
             including alcoholism within the past 6 months (except nicotine and caffeine).

          -  Inadequate communication with the patient.

          -  Under custodial care.

          -  Participation currently in another clinical study or enrolled in another clinical
             study within 30 days prior to this study.

          -  Participants who suffer from an unstable physical disease such as high blood pressure
             or acute, unstable cardiac disease

          -  Use of fluoxetine within 6 weeks of the baseline visit

          -  Use of a Monoamine Oxidase Inhibitor (MAOI) within 2 weeks of the baseline visit

          -  Current use of antidepressant medications during the course of the trial.

          -  Current use of Leponex (Clozapine).

          -  Previous treatment with TMS

          -  Women who are breast-feeding

          -  Known or suspected pregnancy

          -  Women of childbearing potential and not using a medically accepted form of
             contraception when engaging in sexual intercourse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yechiel Levkovitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shalvata Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shlomi Fishman</last_name>
    <phone>972-544596294</phone>
    <email>shlomi@Brainsway.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amit Ginou</last_name>
    <phone>972-526051372</phone>
    <email>amit@Brainsway.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Advanced Mental Health Care Inc. - Juno Beach</name>
      <address>
        <city>Juno Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aron Tendler, MD</last_name>
      <phone>561-333-8884</phone>
      <email>aron.tendler@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aron Tendler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Mental Health Care Inc. - Palm Beach</name>
      <address>
        <city>Palm Beach</city>
        <state>Florida</state>
        <zip>33480</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyssa Sisko</last_name>
      <phone>561-333-8884</phone>
    </contact>
    <contact_backup>
      <phone>561-386-1600</phone>
    </contact_backup>
    <investigator>
      <last_name>Aron Tendler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Mental Health Care Inc. - Royal Palm Beach</name>
      <address>
        <city>Royal Palm Beach</city>
        <state>Florida</state>
        <zip>33411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aron Tendler, MD</last_name>
      <phone>561-333-8884</phone>
      <email>aron.tendler@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aron Tendler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Tibbs</last_name>
      <phone>410-614-1732</phone>
      <email>mtibbs@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Irving Reti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Psychiatric Group</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarit Hovav, MD</last_name>
    </contact>
    <investigator>
      <last_name>Walter J Duffy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Psychiatric Group</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roni Mor</last_name>
      <phone>402-817-2218</phone>
      <email>tms@premierpsych.com</email>
    </contact>
    <investigator>
      <last_name>Walter J Duffy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Uni. Of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jkeonye Moss</last_name>
      <phone>843-876-5141</phone>
      <email>mosjk@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Mark George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Senior Adults Specialty Research</name>
      <address>
        <city>Ausitn</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Meredith Draper, Ph.D</last_name>
      <phone>512-407-8628</phone>
      <email>mdraper@senioradults.net</email>
    </contact>
    <investigator>
      <last_name>Jaron L. Winston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8898</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enisa Arslanagic, MD</last_name>
      <phone>214-648-8659</phone>
      <email>enisa.arslanagic@utsouthwester.edu</email>
    </contact>
    <investigator>
      <last_name>Mustafa M. Husain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Addiction and Mental Health (CAMH)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Maher</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>36434</phone_ext>
      <email>missy.maher@camh.ca</email>
    </contact>
    <investigator>
      <last_name>Daniel Blumberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universität</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariane Hornig</last_name>
      <phone>49 89 5160 5899</phone>
      <email>arianehornig@gmx.de</email>
    </contact>
    <investigator>
      <last_name>Frank Padberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beer Yaacov Mental Health Center</name>
      <address>
        <city>Beer Yaacov</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oded Rosenberg, MD</last_name>
      <phone>972-54-7502109</phone>
      <email>oded35@netvision.net.il</email>
    </contact>
    <investigator>
      <last_name>Pinhas Danon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lev Hasharon</name>
      <address>
        <city>Netanya</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eyal Dahan, MD</last_name>
      <phone>054-7827322</phone>
      <email>eyald@lev-hasharon.co.il</email>
    </contact>
    <investigator>
      <last_name>Igor Oyffe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2012</study_first_posted>
  <last_update_submitted>February 5, 2017</last_update_submitted>
  <last_update_submitted_qc>February 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bipolar Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

